Business Context and Reporting Period
Company: OnKure Therapeutics, Inc. (OKUR)
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2026
Reporting Period: Event-based report regarding a private placement and corporate updates as of March 27, 2026.
Key Financial Metrics and Capital Structure
This filing details a capital raise rather than periodic financial performance. Key metrics include:
- Private Placement Proceeds: Expected aggregate gross proceeds of approximately $150.0 million.
- Securities Issued:
- 26,713,636 shares of Class A Common Stock at $4.15 per share.
- Pre-funded warrants to purchase 9,430,959 shares at $4.1499 per underlying share.
- Use of Proceeds: Funding preclinical and clinical development of next-generation PI3Kα pan-mutant-selective inhibitor candidates (breast cancer and vascular anomalies), working capital, and general corporate purposes.
- Debt and Liquidity: The filing does not provide specific values for existing debt, cash balances, or liquidity ratios. The transaction is intended to enhance liquidity.
Material Changes and Corporate Actions
- Material Definitive Agreement: Entered into a Securities Purchase Agreement with institutional accredited investors. Closing is expected on March 31, 2026.
- Board Composition: Dr. Liam Ratcliffe was elected as a Class I director, effective upon the closing of the Private Placement. He is affiliated with the Lead Investor (AI Biotechnology LLC).
- Lock-Up Provisions: Executive officers and directors agreed not to sell or transfer Common Stock or equivalents for 180 days after the Closing Date or until the effective date of the Registration Statement, whichever is later.
- Registration Rights: Investors received rights to register the resale of shares and warrant shares, with the Company agreeing to file a Registration Statement within 30 days of closing.
Outlook, Management Commentary, and Risks
Development Pipeline Updates
- Next-Generation Programs: The Company plans to submit Investigational New Drug (IND) applications for OKI-345 (breast cancer) and OKI-355 (vascular anomalies) in the first half of 2027.
- OKI-219 Strategy Shift: The PIKture-01 Phase 1a/1b trial for OKI-219 has completed enrollment for dose escalation. Due to progress with pan-mutant inhibitors, the Company is not planning to pursue further independent clinical development of OKI-219 at this time. Mature data from PIKture-01 is expected to be presented by the end of 2026.
Risks and Contingencies
- Closing Conditions: The $150 million raise is subject to customary closing conditions.
- Forward-Looking Statements: Risks include market conditions, ability to advance product candidates, outcomes of preclinical/clinical trials, and potential delays in data reporting.
- Investor Rights: The Lead Investor has the right to designate a board nominee, contingent on maintaining ownership of at least 50% of the Securities purchased.
Investor Verification Checklist
- Verify the actual closing of the Private Placement on or before March 31, 2026, and the final net proceeds received.
- Confirm the effective date of the Registration Statement filed for the resale of the new securities.
- Monitor the submission timeline for IND applications for OKI-345 and OKI-355 (targeted for H1 2027).
- Review the presentation of mature data from the PIKture-01 trial later in 2026 to assess the rationale for halting OKI-219 development.
- Check subsequent filings for any changes to the capital structure or dilution resulting from the exercise of pre-funded warrants.